Dr. Cole is a pediatric neuro-oncologist who has dedicated her career to translational and clinical research, combining her expertise in molecular pathology, cancer genomics, and developmental therapeutics to identify novel treatments for children with cancer.
Dr. Foster’s current research focuses on immunotherapy for pediatric solid and brain tumors. Specifically she is investigating chimeric antigen receptor (CAR) T cell therapy for neuroblastoma, high-grade gliomas, medulloblastomas, diffuse intrinsic pontine gliomas, and other brain tumors. The goals of her research are to develop pre-clinical CAR T cells for translation into clinical trials to help these devastating tumors.
In 2016, one million or more volunteers may begin enrolling in one of the largest long-term medical research studies ever planned. It aims to inform future therapies targeted to the molecular, environmental, and behavioral factors that contribute to diverse diseases.
Tom Curran, PhD, FRS, of The Children’s Hospital of Philadelphia Research Institute, contributed to an article in the Journal of Clinical Oncology assessing the efficacy of a drug called vismodegib (Erivedge) in a subgroup of patients with recurrent medulloblastoma.
At the 13th Annual Dream & Promise Gala, set to be held tonight in New York, the Children’s Brain Tumor Foundation will honor Tom Curran, PhD, FRS, with the 2015 Fred J. Epstein, MD, Lifetime Achievement Award.
A world-renowned cancer investigator at The Children's Hospital of Philadelphia will be honored by the American Association for Cancer Research as it inaugurates the first class of the Fellows of the AACR Academy.
Research in the Cole Lab focuses on identifying therapeutic vulnerabilities within molecularly defined subsets of pediatric central nervous system malignancies. The long-term goal of the lab is to identify effective therapies and improve the cure rate of children with malignant brain tumors.